Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.
CONCLUSION: Before DAA therapy is initiated in a patient who has cirrhosis or has undergone treatment for HCC with curative intent, a de novo or recurrent HCC should be meticulously excluded. Even after SVR, these patients still need intensive follow-up and surveillance.
PMID: 28927498 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
More News: Antiviral Therapy | Cancer | Cancer & Oncology | Carcinoma | Cirrhosis | Databases & Libraries | General Medicine | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | History of Medicine | Liver Cancer | Virology